The objectives of this program are to train graduate students for a research career in academia, pharmaceutical companies, or government research agencies in the general area of pharmacology, with a focus on signal transduction, structural biology, neuropharmacology, and drug discovery. The program is designed to adapt to students'interest a will provide a strong biochemical, neuroscience, biophysical, and physiological background that will enable the student (1) to understand the molecular basis of currently used therapeutics;(2) to design experiments (a) to identify potential targets;and (b) t elucidate signal transduction mechanisms of new physiological agents or new therapeutics, (c) to solve macromolecular structures of interest in pharmacology, and (d) use modern tools for drug discovery. To achieve these ends, the pharmacology program at Yale was changed with new faculty and courses. Modern techniques in molecular pharmacology, cell and molecular biology, structural biology, chemistry, biochemistry, physiology and biophysics will be available to the trainee to achieve these goals. The trainee will have constant exposure to a variety of research programs of the faculty and over one hundred senior postdoctoral fellows who provide an additional resource for the trainees.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Institutional National Research Service Award (T32)
Project #
5T32GM007324-37
Application #
8492089
Study Section
National Institute of General Medical Sciences Initial Review Group (BRT)
Program Officer
Okita, Richard T
Project Start
1975-07-01
Project End
2017-06-30
Budget Start
2013-07-01
Budget End
2014-06-30
Support Year
37
Fiscal Year
2013
Total Cost
$357,236
Indirect Cost
$16,980
Name
Yale University
Department
Pharmacology
Type
Schools of Medicine
DUNS #
043207562
City
New Haven
State
CT
Country
United States
Zip Code
06520
Huet-Calderwood, Clotilde; Rivera-Molina, Felix; Iwamoto, Daniel V et al. (2017) Novel ecto-tagged integrins reveal their trafficking in live cells. Nat Commun 8:570
Mo, Elizabeth S; Cheng, Qianni; Reshetnyak, Andrey V et al. (2017) Alk and Ltk ligands are essential for iridophore development in zebrafish mediated by the receptor tyrosine kinase Ltk. Proc Natl Acad Sci U S A 114:12027-12032
Bauer, Ashley J; Martin, Kathleen A (2017) Coordinating Regulation of Gene Expression in Cardiovascular Disease: Interactions between Chromatin Modifiers and Transcription Factors. Front Cardiovasc Med 4:19
Grabi?ska, Kariona A; Edani, Ban H; Park, Eon Joo et al. (2017) A conserved C-terminal RXG motif in the NgBR subunit of cis-prenyltransferase is critical for prenyltransferase activity. J Biol Chem 292:17351-17361
Smithy, James W; Moore, Lauren M; Pelekanou, Vasiliki et al. (2017) Nuclear IRF-1 expression as a mechanism to assess ""Capability"" to express PD-L1 and response to PD-1 therapy in metastatic melanoma. J Immunother Cancer 5:25
Panaccione, Alex; Zhang, Yi; Ryan, Molly et al. (2017) MYB fusions and CD markers as tools for authentication and purification of cancer stem cells from salivary adenoid cystic carcinoma. Stem Cell Res 21:160-166
Langdon, Casey G; Platt, James T; Means, Robert E et al. (2017) Combinatorial Screening of Pancreatic Adenocarcinoma Reveals Sensitivity to Drug Combinations Including Bromodomain Inhibitor Plus Neddylation Inhibitor. Mol Cancer Ther 16:1041-1053
Puleo, David E; Kucera, Kaury; Hammarén, Henrik M et al. (2017) Identification and Characterization of JAK2 Pseudokinase Domain Small Molecule Binders. ACS Med Chem Lett 8:618-621
Moore, Lauren M; England, Allison; Ehrlich, Barbara E et al. (2017) Calcium Sensor, NCS-1, Promotes Tumor Aggressiveness and Predicts Patient Survival. Mol Cancer Res 15:942-952
Wali, Vikram B; Langdon, Casey G; Held, Matthew A et al. (2017) Systematic Drug Screening Identifies Tractable Targeted Combination Therapies in Triple-Negative Breast Cancer. Cancer Res 77:566-578

Showing the most recent 10 out of 65 publications